Home/Indications/Atrial Flutter

Atrial Flutter

1 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Market Leaders

AOP HLTH US

original drugs

Clinical Pipeline by Phase

8 industry-sponsored trials across 7 sponsors

Showing 2 of 2 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Bristol-Myers Squibb	—	—	COMPLETED	2023-06-30	NCT04126486
Biotronik, Inc.	Home Monitoring Guided OAC	—	TERMINATED	2013-06	NCT00559988

Showing 2 of 2 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Abbott Medical Devices	—	—	COMPLETED	2012-04	NCT01401361
Abbott Medical Devices	—	—	COMPLETED	2010-08	NCT00984204

Showing 3 of 3 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Laguna Pharmaceuticals, Inc.	Vanoxerine	—	COMPLETED	2013-09	NCT01691313
Portola Pharmaceuticals	Amiodarone	—	COMPLETED	2010-12	NCT01229254
AstraZeneca	AZD1305	—	COMPLETED	2008-06	NCT00616629

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Biosense Webster, Inc.	—	—	COMPLETED	2014-11	NCT02257060

Novel Drugs by Company (New molecular entities)

AOP HLTH US 1 drug

RAPIBLYK

LANDIOLOL HYDROCHLORIDE

NDA 2024

Reformulations (10 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

HQ SPCLT PHARMA

T5 2016

ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER